Suppr超能文献

医疗补助处方共付政策的意外后果。

Unintended consequences of a Medicaid prescription copayment policy.

机构信息

*Division of Emergency Medicine, Harborview Medical Center, University of Washington, Seattle, WA †Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

出版信息

Med Care. 2014 May;52(5):422-7. doi: 10.1097/MLR.0000000000000119.

Abstract

BACKGROUND AND OBJECTIVES

Medication copayments can influence patient choices. We evaluated 2 copayment policies implemented by Massachusetts Medicaid incentivizing the use of selected generic medications.

RESEARCH DESIGN AND MEASURES

In 2009, Massachusetts Medicaid copayments were $1 for generics and $3 for brands. On February 1, 2009, copayments for generic antihypertensives, antihyperlipidemics, and hypoglycemics (target medications) remained at $1, whereas copayments for all nontarget generics increased to $2 (policy #1) and $3 on July 1, 2010 (policy #2). Using state-level, aggregate prescription data, we developed interrupted time-series models with controls to evaluate the impact of these policies on use of target generics, target brands, and nontarget essential medications (defined as medications required for ongoing treatment of serious medical conditions).

RESULTS

After policy #1, target generic use increased by 0.93% (P<0.001) with a subsequent quarterly slope decrease of -0.16% (P<0.01); policy #2 led to a slope increase of 0.20% (P<0.01) for target generics; increase in target generics attributable to policy changes was 28,000 prescriptions per year. Neither policy affected target brand use. For nontarget essential generics, there was a -0.27% (P<0.001) quarterly slope decrease after policy #1 and a 0.32% (P<0.01) slope increase after policy #2 with total decrease attributable to policy changes of 127,300 prescriptions per year. For nontarget essential brands, there was a level increase of 0.91% (P<0.001) after policy #1 with increased use attributable to policy changes of 98,300 prescriptions per year.

CONCLUSIONS

Two copayment policies designed to encourage use of selected generic medications modestly increased their use; however, there was a shift in other essential medications from generics to brands, which could increase Medicaid costs. When adjusting copayments, careful consideration must be given to unintended consequences of specific policy structures.

摘要

背景与目的

药物自付额可能会影响患者的选择。我们评估了马萨诸塞州医疗补助计划实施的 2 项自付额政策,以激励使用选定的通用药物。

研究设计和措施

2009 年,马萨诸塞州医疗补助计划的通用药物自付额为 1 美元,品牌药物自付额为 3 美元。2009 年 2 月 1 日,降压药、降脂药和降糖药(目标药物)的通用药物自付额仍为 1 美元,而所有非目标通用药物的自付额增加至 2 美元(政策 1),并于 2010 年 7 月 1 日增加至 3 美元(政策 2)。我们使用州级汇总处方数据,开发了具有对照的中断时间序列模型,以评估这些政策对目标通用药物、目标品牌药物和非目标必需药物(定义为治疗严重疾病所需的持续治疗药物)使用的影响。

结果

政策 1 实施后,目标通用药物的使用增加了 0.93%(P<0.001),随后每季度斜率下降 0.16%(P<0.01);政策 2 导致目标通用药物斜率增加 0.20%(P<0.01);政策变化导致目标通用药物的增加量为每年 28000 个处方。这两项政策都没有影响目标品牌药物的使用。对于非目标必需的通用药物,政策 1 实施后,每季度斜率下降 0.27%(P<0.001),政策 2 实施后斜率增加 0.32%(P<0.01),政策变化导致每年的处方减少 127300 张。对于非目标必需的品牌药物,政策 1 实施后,药物水平增加了 0.91%(P<0.001),政策变化导致每年的处方增加 98300 张。

结论

两项旨在鼓励使用特定通用药物的自付额政策适度增加了它们的使用;然而,其他必需药物从通用药物转向了品牌药物,这可能会增加医疗补助计划的成本。在调整自付额时,必须仔细考虑特定政策结构的意外后果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验